Jesus Troya

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Rethinking HIV resistance in the era of long-acting therapy: from isolated events to durable exposure.

Rethinking HIV resistance in the era of long-acting therapy: from isolated events to durable exposure.

Journal: AIDS (London, England)

Published: May 20, 2026

Resistance Framing, Temporal Risk Assumptions, and Public Health Priorities in the Long-Acting Antiretroviral Era.

Resistance Framing, Temporal Risk Assumptions, and Public Health Priorities in the Long-Acting Antiretroviral Era.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 08, 2026

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Journal: HIV medicine

Published: November 19, 2025

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.

Journal: Journal of the International AIDS Society

Published: October 11, 2025

Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead.

Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead.

Journal: The Journal of antimicrobial chemotherapy

Published: August 12, 2025

Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.

Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.

Journal: HIV medicine

Published: July 28, 2025

A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study).

A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study).

Journal: The Journal of antimicrobial chemotherapy

Published: July 17, 2025

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Journal: AIDS (London, England)

Published: July 02, 2025

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Journal: AIDS (London, England)

Published: July 02, 2025

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 24, 2025

Showing 1-12 of 73

Last Updated: 09/26/2026